Clinical Trial: Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015671) titled 'Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects' on June 03.

Brief Summary: This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone(R) (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone(R) (Spironolactone) taken together in healthy subjects.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Bioequivalence Study in Healthy S...